Compare GSK plc (GSK) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs BIO-TECHNE Corp — how do they compare? GSK plc trades at $46.65 (market cap $95.18B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: GSK plc is far larger — about 8.4× BIO-TECHNE Corp's market cap, and GSK plc pays the higher dividend (3.86%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and BIO-TECHNE Corp for 63 Days on average.
| GSK | TECH | |
|---|---|---|
Market Cap | $95.18B | $11.37B |
Volume | 5,852,596 | 3,153,511 |
Sector | Health | Health |
52-Week High | $61.18 | $72.61 |
52-Week Low | $43.24 | $43.31 |
Typical Hold Time | 93 Days | 63 Days |
Enterprise Value | $115.25B | $11.40B |
Dividend Yield | 3.86% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.02, up 0.9% today, with a bearish technical signal but strong fundamentals. The company reported revenue of $32.67B in 2025 with a net income margin of 14.52% and has beaten EPS estimates for three consecutive quarters. Recent news highlights strategic oncology investments and a $750M deal for a cancer therapy, signaling growth initiatives.
The outlook is mixed: solid profitability and a reasonable P/E of 15.1 support value, but technical indicators show bearish pressure near key support at $46. Risks include patent expirations and competitive pressures, while analyst sentiment is cautious with 31% buy ratings. Upside depends on pipeline execution and cost savings.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
